Concord Drugs Ltd Stock Analysis

Small Cap
Evaluated by 57 users | BSE: 538965 | NSE: |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
Return on Capital Employed 13.43%11.05%5.53%5.13%7.82%10.29%5.34%4.88%4.62%4.27%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 24.127.728.1344050.757.551.848.151.3
Y-o-Y Gr. Rt.-14.7%1.5%21%17.9%26.6%13.4%-9.9%-7.2%6.8%
Adjusted EPS (Rs.)
Y-o-Y Gr. Rt.--24.1%-34.6%-67.4%104.3%156.3%-91.1%86.4%26.8%-26.9%
Book Value per Share (Rs.) 13.715.5216.9617.4218.3820.826.2224.5829.4526.86
Adjusted Net Profit 1.61.610.
Net Op. Cash Flow (Rs. Cr.) 0-
Debt to Cash Flow from Ops 176.89-2.4913.287.5812.165.539.061.988.234.44
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Concord Drugs Ltd. should be analysed on a Standalone basis
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 8.8%5.1%-3.7%6.8%
Adjusted EPS -20.2%-16.9%20%-26.9%
Book Value per Share
Share Price - -8.1% 16.3% 100.6%
Key Financial Parameter
Performance Ratio Colour Code Guide
Return on Equity (%) 15.5713.77.72.354.9912.560.941.691.921.41
Operating Profit Margin (%) 10.9211.378.259.5117.5516.369.588.797.616.51
Net Profit Margin (%) 6.755.763.7111.743.520.280.630.850.64
Debt to Equity 0.340.711.281.371.61.330.810.710.420.41
Working Capital Days 0189276244272263251474620416
Cash Conversion Cycle 093117105107128102129146186
Entity Percentage Holding
Promoters 44.38%
Non-Institutions 55.62%
Pledged *
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Concord Drugs Ltd's performance infers:

Concord Drugs Ltd earnings have declined by -16.9%, whereas share price has depreciated -8.1% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

Data is not available for this company

No data to display
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323